Clinical Pharmacokinetics

, Volume 29, Supplement 1, pp 45–52 | Cite as

Drug Interactions and the Cytochrome P450 System

The Role of Cytochrome P450 2C19
  • David A. Flockhart


On the basis of the data currently available, the wild type cytochrome P450 2C19 (CYP2C19) gene appears to be absent in 2 to 6% of Caucasian populations and up to 20% of Asian populations. A poor metaboliser phenotype therefore results. The CYP2C19 phenotype can be determined clinically by use of either mephenytoin or omeprazole as the probe. Since both drugs are metabolised primarily by CYP2C19 in human liver microsomes, they are both useful, competitive inhibitors of CYP2C19 activity available to researchers working in vitro. The 2 known mutant alleles of CYP2C19 do not result in the expression of active enzyme and can be tested by using small samples of whole blood. No rapid mutants have been identified. A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine. Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.


Adis International Limited Fluoxetine Omeprazole Fluvoxamine Clomipramine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archiv Biochem Biophys 1993; 306(1): 240–5CrossRefGoogle Scholar
  2. 2.
    De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 19–22Google Scholar
  3. 3.
    De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594–8PubMedGoogle Scholar
  4. 4.
    Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26: 753–9PubMedCrossRefGoogle Scholar
  5. 5.
    Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773–80PubMedCrossRefGoogle Scholar
  6. 6.
    Wedlund PJ, Sweetman BJ, Wilkinson GR, et al. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987; 15: 277–9PubMedGoogle Scholar
  7. 7.
    Wedlund PJ, Sweetman BJ, McAllister CB, et al. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984; 307: 121–7PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang Y, Blouin RA, McNamara PJ, et al. Limitation to the use of the urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991; 31: 350–2PubMedCrossRefGoogle Scholar
  9. 9.
    Tybring G, Bertillson L. A methodological investigation on the stimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992; 2: 241–3PubMedCrossRefGoogle Scholar
  10. 10.
    Balian J, Soukhova N, Hewett J, et al. Omeprazole as a probe for the S-mephenytoin polymorphism. Clin Pharmacol Ther 1995; 57: 662–9PubMedCrossRefGoogle Scholar
  11. 11.
    Andersson T, Regårdh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415–6PubMedCrossRefGoogle Scholar
  12. 12.
    Doshi BS, Kulkarni RD, Chauhan BL, et al. Frequency of impaired mephenytoin 4′-hydroxylation in an Indian population. Br J Clin Pharmacol 1990; 30: 779–80PubMedCrossRefGoogle Scholar
  13. 13.
    Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483–7PubMedCrossRefGoogle Scholar
  14. 14.
    Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402PubMedCrossRefGoogle Scholar
  15. 15.
    Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97PubMedCrossRefGoogle Scholar
  16. 16.
    Weerasuriya K, Jayakody RL, Smith CAD, et al. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994; 38: 466–70PubMedCrossRefGoogle Scholar
  17. 17.
    Sohn D-R, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160–9PubMedCrossRefGoogle Scholar
  18. 18.
    Clasen K, Madsen L, Brøsen K, et al. Sparteine and mephenytoin oxidation: genetic polymorphisms in East and West Greenland. Clin Pharmacol Ther 1991; 49: 624–31PubMedCrossRefGoogle Scholar
  19. 19.
    Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988; 35: 167–71PubMedCrossRefGoogle Scholar
  20. 20.
    Hadidi H, Irshaid YM, Woosley RL, et al. S-mephenytoin hydroxylation phenotypes in a Jordanian population. Clin Pharmacol Ther 1995. In pressGoogle Scholar
  21. 21.
    Pollock BG, Perel JM, Kirshner JM, et al. S-mephenytoin hydroxylation in older Americans. Eur J Pharmacol 1991; 40: 609–11Google Scholar
  22. 22.
    Guttendorf RJ, Britto M, Blouin RA, et al. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 1990; 29: 373–80PubMedCrossRefGoogle Scholar
  23. 23.
    Sanz EJ, Villén T, Alm C, et al. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after co-administration with debrisoquine. Clin Pharmacol Ther 1989; 45: 495–9PubMedCrossRefGoogle Scholar
  24. 24.
    Drøhse A, Bathum L, Brøsen K, et al. Mephenytoin and sparteine oxidations: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989; 27: 620–5PubMedCrossRefGoogle Scholar
  25. 25.
    Inaba T, Jurima M, Nakano M, et al. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther 1984; 36: 670–6PubMedCrossRefGoogle Scholar
  26. 26.
    Edeki TI, Hajiloo L, Butler M, et al. S-mephenytoin 4-hydroxylation in African Americans [abstract]. J Clin Pharmacol 1994; 34: 102Google Scholar
  27. 27.
    Andersson T, Regårdh C-G, Lou Y-C, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31PubMedCrossRefGoogle Scholar
  28. 28.
    Bertillson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348–55CrossRefGoogle Scholar
  29. 29.
    Yasumori T, Nagata K, Yang SK, et al. Cytochrome P450-mediated metabolism of diazepam in human and rat: involvement of human CYP2C in Af-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993; 3: 291–301PubMedCrossRefGoogle Scholar
  30. 30.
    Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85PubMedCrossRefGoogle Scholar
  31. 31.
    Jacqz E, Hall SD, Branch RA, et al. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 1986; 39: 646–53PubMedCrossRefGoogle Scholar
  32. 32.
    Ward SA, Walle T, Walle UK, et al. Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989; 45: 72–9PubMedCrossRefGoogle Scholar
  33. 33.
    Skjelbo E, Brøsen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49: 18–23PubMedCrossRefGoogle Scholar
  34. 34.
    Nielsen KK, Brøsen K, Hansin MGJ, et al. Single dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518–27PubMedCrossRefGoogle Scholar
  35. 35.
    Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350–8PubMedCrossRefGoogle Scholar
  36. 36.
    Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402–11PubMedCrossRefGoogle Scholar
  37. 37.
    Cavuto JN, Soukhova N, Hewett J, et al. Effect of omeprazole on theophylline clearance in poor metabolizers of omeprazole [abstract]. Clin Pharmacol Ther 1994; 57: 215Google Scholar
  38. 38.
    Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 676–7CrossRefGoogle Scholar
  39. 39.
    Flockhart DA, Clauw DJ, Buchert Sale E, et al. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994; 56: 398–405PubMedCrossRefGoogle Scholar
  40. 40.
    Gram LF. Drug therapy: fluoxetine. N Engl J Med 1994; 331: 1354–61PubMedCrossRefGoogle Scholar
  41. 41.
    Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 — the source of the sparteine/debrisoquine oxidation polymorphism [letter]. Br J Clin Pharmacol 1991; 32: 136–7PubMedCrossRefGoogle Scholar
  42. 42.
    Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4PubMedCrossRefGoogle Scholar
  43. 43.
    Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471–6PubMedCrossRefGoogle Scholar
  44. 44.
    Fleishaker JC, Hulst LK. Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers [abstract]. Pharm Res 1992; 9: S292CrossRefGoogle Scholar
  45. 45.
    Van Harten J, Holland RL, Wesnes K. Influence of multiple dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines lorazepam and bromazepam: a randomized crossover study [abstract]. Eur Neuropsychopharmacol 1992; 2: 381CrossRefGoogle Scholar
  46. 46.
    Spina E, Pollicino AM, Avenoso A, et al. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993; 13: 167–71PubMedGoogle Scholar
  47. 47.
    Hartter S, Arand M, Oesch F, et al. Noncompetitive inhibition of clomipramine N-demethylation by fluvoxamine. Psychopharmacology 1995; 117: 149–53PubMedCrossRefGoogle Scholar
  48. 48.
    Nielsen KK, Brøsen K, Hansen MG, et al. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518–27PubMedCrossRefGoogle Scholar
  49. 49.
    Lemoine A, Gautier JC, Azoulay D, et al. The major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and 3A4 in human liver. Mol Pharmacol 1993; 43: 827–32PubMedGoogle Scholar
  50. 50.
    Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597–606PubMedCrossRefGoogle Scholar
  51. 51.
    Miners JO, Veronese JO, Birkert JO. In vitro approaches for the prediction of human drug metabolism. Annu Rep Med Chem 1994; 29: 307–16CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • David A. Flockhart
    • 1
  1. 1.Division of Clinical Pharmacology, Departments of Pharmacology and MedicineGeorgetown University Medical CenterWashington DCUSA

Personalised recommendations